Creative Medical Technology Holdings, Inc. Files 2023 Annual Report
Ticker: CELZ · Form: 10-K · Filed: Mar 22, 2024 · CIK: 1187953
Sentiment: neutral
Topics: 10-K, Annual Report, Financials, Creative Medical Technology, CELZ
TL;DR
<b>Creative Medical Technology Holdings, Inc. has filed its annual 10-K report for the fiscal year ending December 31, 2023.</b>
AI Summary
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed a Annual Report (10-K) with the SEC on March 22, 2024. The company filed its 10-K for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. Previous company name was Jolley Marketing Inc., changed on September 10, 2002. Incorporated in Nevada. Business and mailing address is 211 E. Osborn Rd., Phoenix, AZ 85012.
Why It Matters
For investors and stakeholders tracking CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of the company's financial performance, operations, and strategic initiatives for the past fiscal year. Investors and stakeholders can use this report to assess the company's financial health, identify potential risks, and make informed investment decisions.
Risk Assessment
Risk Level: low — CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant financial or operational disclosures that would indicate a high-risk profile.
Analyst Insight
Review the full 10-K filing for detailed financial statements, management discussion, and risk factors to understand the company's current standing and future outlook.
Key Numbers
- 2023-12-31 — Fiscal Year End (Reporting period)
- 2024-03-22 — Filing Date (Date of submission)
- 0001187953 — Central Index Key (Company identifier)
- 001-41120 — SEC File Number (SEC registration number)
Key Players & Entities
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (company) — Filer name
- CELZ (company) — Ticker symbol
- JOLLEY MARKETING INC. (company) — Former company name
- 2023-12-31 (date) — Fiscal year end
- 2024-03-22 (date) — Filing date
- 211 E. OSBORN RD. (address) — Business address
- PHOENIX (location) — Business address city
- NV (state) — State of incorporation
FAQ
When did CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. file this 10-K?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filed this Annual Report (10-K) with the SEC on March 22, 2024.
What is a 10-K filing?
A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ).
Where can I read the original 10-K filing from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..
What are the key takeaways from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s 10-K?
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filed this 10-K on March 22, 2024. Key takeaways: The company filed its 10-K for the fiscal year ending December 31, 2023.. The filing covers the period from January 1, 2023, to December 31, 2023.. Previous company name was Jolley Marketing Inc., changed on September 10, 2002..
Is CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. a risky investment based on this filing?
Based on this 10-K, CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. presents a relatively low-risk profile. The filing is a standard annual report (10-K) and does not contain immediate, significant financial or operational disclosures that would indicate a high-risk profile.
What should investors do after reading CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s 10-K?
Review the full 10-K filing for detailed financial statements, management discussion, and risk factors to understand the company's current standing and future outlook. The overall sentiment from this filing is neutral.
How does CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. compare to its industry peers?
Creative Medical Technology Holdings, Inc. operates in the Biological Products sector, focusing on products that are not diagnostic substances.
Are there regulatory concerns for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.?
The company is subject to SEC regulations for public filings, including the requirement to submit a comprehensive annual report (10-K).
Industry Context
Creative Medical Technology Holdings, Inc. operates in the Biological Products sector, focusing on products that are not diagnostic substances.
Regulatory Implications
The company is subject to SEC regulations for public filings, including the requirement to submit a comprehensive annual report (10-K).
What Investors Should Do
- Thoroughly review the financial statements and Management's Discussion and Analysis (MD&A) section of the 10-K.
- Analyze the risk factors section to understand potential challenges and uncertainties facing the company.
- Compare the 2023 results with previous years to identify trends in revenue, expenses, and profitability.
Key Dates
- 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
- 2024-03-22: Filing Date — Date the 10-K report was officially submitted to the SEC.
Year-Over-Year Comparison
This filing is the 2023 annual report (10-K), providing updated information compared to previous filings.
Filing Stats: 4,447 words · 18 min read · ~15 pages · Grade level 13.3 · Accepted 2024-03-22 16:45:53
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CELZ The NASDAQ Stock Mar
- $22.50 — ants"), at a combined offering price of $22.50 per share of common stock/Pre-Funded Wa
- $17,000,000 — roceeds to the Company of approximately $17,000,000. The transaction was effected pursuant
- $20.00 — ive-year term, and an exercise price of $20.00 per share. The Pre-Funded Warrants did
- $1,360,000 — a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 1
Filing Documents
- celz_10k.htm (10-K) — 968KB
- celz_ex44.htm (EX-4.5) — 20KB
- celz_ex108.htm (EX-10.8) — 9KB
- celz_ex311.htm (EX-31.1) — 10KB
- celz_ex312.htm (EX-31.2) — 10KB
- celz_ex321.htm (EX-32.1) — 4KB
- celz_ex322.htm (EX-32.2) — 4KB
- celz_ex109img4.jpg (GRAPHIC) — 306KB
- celz_ex109img6.jpg (GRAPHIC) — 243KB
- celz_ex109img3.jpg (GRAPHIC) — 284KB
- celz_ex109img2.jpg (GRAPHIC) — 174KB
- celz_ex109img12.jpg (GRAPHIC) — 29KB
- celz_ex109img11.jpg (GRAPHIC) — 24KB
- celz_ex109img10.jpg (GRAPHIC) — 43KB
- celz_ex109img1.jpg (GRAPHIC) — 228KB
- celz_ex109img7.jpg (GRAPHIC) — 263KB
- celz_ex109img8.jpg (GRAPHIC) — 303KB
- celz_ex109img9.jpg (GRAPHIC) — 55KB
- celz_10kimg1.jpg (GRAPHIC) — 16KB
- celz_10kimg2.jpg (GRAPHIC) — 31KB
- celz_10kimg3.jpg (GRAPHIC) — 31KB
- celz_ex109img5.jpg (GRAPHIC) — 242KB
- 0001477932-24-001431.txt ( ) — 7085KB
- celz-20231231.xsd (EX-101.SCH) — 37KB
- celz-20231231_lab.xml (EX-101.LAB) — 241KB
- celz-20231231_cal.xml (EX-101.CAL) — 34KB
- celz-20231231_pre.xml (EX-101.PRE) — 192KB
- celz-20231231_def.xml (EX-101.DEF) — 98KB
- celz_10k_htm.xml (XML) — 429KB
Risk Factors
Risk Factors 22 1B. Unresolved Staff Comments 32 2.
Legal Proceedings
Legal Proceedings 32 4. Mine Safety Disclosures 32 Part II 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 33 6.
Selected Financial Data
Selected Financial Data 35 7.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 7A.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 40 8.
Financial Statements and Supplementary Data
Financial Statements and Supplementary Data F-1 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 41 9A.
Controls and Procedures
Controls and Procedures 41 9B. Other Information 41 Part III 10. Directors, Executive Officers and Corporate Governance 42 11.
Executive Compensation
Executive Compensation 42 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42 13. Certain Relationships and Related Transactions and Director Independence 42 14. Principal Accountant Fees and Services 42 Part IV 15. Exhibits, Financial Statement Schedules 43
Signatures
Signatures 45 3 Table of Contents
Business
Item 1. Business Overview We are a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following: Our subsidiary, Creative Medical Technologies, Inc. ("CMT"), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction ("ED"), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing "re-programmed" stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities. We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem and FemCelz disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem and FemCelz kits are currently available through physicians at eight locations in the United States. In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz platform (CELZ-100), that utilize a patient's own extracted immune cells that are then "reprogrammed/supercharged" by culturing them outside the patient's body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties (or "supercharges" them) providing them with the ability to treat multiple indications. We have va